Effects of Calcium Channel Blockers on the Contractile Response to Dihydroergotamine in Isolated Human Femoral Veins

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1987 May 1

PMID 3614388

Authors

E Glusa

F Markwardt

Affiliations

Soon will be listed here.

Abstract

Contractions induced in spirally cut human postmortem femoral veins by dihydroergotamine, noradrenaline, or 5-hydroxytryptamine (5-HT) were measured isometrically. The influence of calcium channel blockers (verapamil, diltiazem and nifedipine), lanthanum chloride and withdrawal of external calcium on the contractile response of veins to dihydroergotamine was investigated. The agonists noradrenaline and 5-HT were studied in comparison. Verapamil and nifedipine up to a concentration of 1 mumol/l caused a shift to the right of the cumulative concentration-response curves for noradrenaline and 5-HT with a reduction of the maximum contraction. Diltiazem affected the contractile response to 5-HT slightly. The venocontractions induced by dihydroergotamine at a concentration of 0.03 mumol/l were inhibited by the calcium channel blockers in a concentration-dependent manner. Verapamil was most effective, followed by nifedipine and diltiazem. In dihydroergotamine-precontracted veins nifedipine produced a more pronounced relaxation than verapamil. Lanthanum chloride (5 mmol/l) inhibited the dihydroergotamine-induced contraction by about 90%. Exposure of veins to a calcium-free medium for 30 min resulted in an inhibition of the dihydroergotamine-induced venocontraction by more than 90%. The addition of calcium ions to the medium caused an increase in the contraction with a maximum which closely resembled that of the control. The present studies demonstrate that the contractile response of human femoral veins to dihydroergotamine depends to a great extent on extracellular calcium. However, the calcium channel blockers verapamil, diltiazem and nifedipine, inhibit the agonist-induced venocontractions in part only.

References

AFFOLTER H, BURKARD W, Pletscher A . Verapamil, an antagonist at 5-hydroxytryptamine receptors of human blood platelets. Eur J Pharmacol. 1985; 108(2):157-62. DOI: 10.1016/0014-2999(85)90720-4. View

FLECKENSTEIN A . Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Annu Rev Pharmacol Toxicol. 1977; 17:149-66. DOI: 10.1146/annurev.pa.17.040177.001053. View

Cavero I, Shepperson N, Langer S . Differential inhibition of vascular smooth muscle responses to alpha 1- and alpha 2-adrenoceptor agonists by diltiazem and verapamil. Circ Res. 1983; 52(2 Pt 2):I69-76. View

Glusa E, Markwardt F . Dual effect of dihydroergotamine and dihydroergotoxin in isolated human femoral veins and arteries. Pharmacology. 1982; 24(5):287-93. DOI: 10.1159/000137609. View

Auguet M, Delaflotte S, Clostre F, Defeudis F . Verapamil as an apparent competitive antagonist of the serotonin receptor of rabbit isolated aorta. Gen Pharmacol. 1986; 17(2):133-5. DOI: 10.1016/0306-3623(86)90129-1. View

Rimele T, Vanhoutte P . Effects of inhibitors of arachidonic acid metabolism and calcium entry on responses to acetylcholine, potassium and norepinephrine in the isolated canine saphenous vein. J Pharmacol Exp Ther. 1983; 225(3):720-8. View

Motulsky H, Snavely M, Hughes R, Insel P . Interaction of verapamil and other calcium channel blockers with alpha 1- and alpha 2-adrenergic receptors. Circ Res. 1983; 52(2):226-31. DOI: 10.1161/01.res.52.2.226. View

Glusa E, Markwardt F . Studies on 5-hydroxytryptamine receptors on isolated human femoral veins and arteries and the influence of dihydroergotamine. Pharmacology. 1984; 29(6):336-42. DOI: 10.1159/000138033. View

van Breemen C, Hwang O, Meisheri K . The mechanism of inhibitory action of diltiazem on vascular smooth muscle contractility. J Pharmacol Exp Ther. 1981; 218(2):459-63. View

10.

Dagher F, Pais S, Richards W, Queral L . Severe unilateral ischemia of the lower extremity caused by ergotamine: treatment with nifedipine. Surgery. 1985; 97(3):369-73. View

11.

Kalkman H, van Gelderen E, Timmermans P, van Zwieten P . Involvement of alpha 1- and alpha 2-adrenoceptors in the vasoconstriction caused by ergometrine. Eur J Pharmacol. 1982; 78(1):107-11. DOI: 10.1016/0014-2999(82)90377-6. View

12.

Mikkelsen E, Pedersen O, Ostergaard J, Pedersen S . Effects of ergotamine on isolated human vessels. Arch Int Pharmacodyn Ther. 1981; 252(2):241-52. View

13.

Muller-Schweinitzer E . Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins. Naunyn Schmiedebergs Arch Pharmacol. 1984; 327(4):299-303. DOI: 10.1007/BF00506240. View

14.

Jim K, Macia R, Matthews W . An evaluation of the ability of a series of full alpha-1 adrenoceptor agonists to release internal calcium in venous smooth muscle. J Pharmacol Exp Ther. 1985; 235(2):377-81. View

15.

Jim K, Matthews W . Role of extracellular calcium in contractions produced by activation of postsynaptic alpha-2 adrenoceptors in the canine saphenous vein. J Pharmacol Exp Ther. 1985; 234(1):161-5. View

16.

de Mey J, Vanhoutte P . Uneven distribution of postjunctional alpha 1-and alpha 2-like adrenoceptors in canine arterial and venous smooth muscle. Circ Res. 1981; 48(6 Pt 1):875-84. DOI: 10.1161/01.res.48.6.875. View

17.

van Breemen C, Aaronson P, Loutzenhiser R, Meisheri K . Ca2+ movements in smooth muscle. Chest. 1980; 78(1 Suppl):157-65. DOI: 10.1378/chest.78.1_supplement.157. View

18.

Kalkman H, Timmermans P, van Zwieten P . The vasopressor response to serotonin (5-HT) in rats; its dependency upon extracellular calcium. Arch Int Pharmacodyn Ther. 1984; 268(2):232-41. View

19.

Bou J, Massingham R . Effect of diltiazem upon contractile responses to phenylephrine, cirazoline, Sgd 101/75, St 587 and B-HT 920 in rabbit aorta and dog saphenous vein preparations. Eur J Pharmacol. 1986; 121(3):319-25. DOI: 10.1016/0014-2999(86)90252-9. View

20.

Cooke J, Rimele T, Flavahan N, Vanhoutte P . Nimodipine and inhibition of alpha adrenergic activation of the isolated canine saphenous vein. J Pharmacol Exp Ther. 1985; 234(3):598-602. View